Novo Nordisk's Pill Breakthrough
Novo Nordisk, the Danish pharmaceutical giant, has seen a surge in sales following the launch of its new weight-loss pill, marking a potential turning point in the GLP-1 drug landscape. In its first earnings report since releasing an oral alternative to its blockbuster injectable Wegovy, the company reported 1.3 million prescriptions for the pill in the U.S. during the first quarter of 2026. This performance has prompted Novo to raise its full-year guidance, signaling optimism about the drug's broader appeal.
The pill, which is now available in the U.S., is expected to expand internationally in the second half of 2026, extending its reach to new markets. CEO Mike Doustdar highlighted the approval of a high-dose version of Wegovy from the U.S. Food and Drug Administration in March, designed for more significant weight loss. This dual strategy aims to capture both injection and oral medication users, with the company emphasizing that the pill is attracting new patients rather than cannibalizing existing injection sales.
Financial Performance and Guidance
Novo Nordisk reported a 32% increase in sales on a constant currency basis and a 65% rise in operating profit for the first quarter, outperforming internal expectations. Adjusted figures show a 4% sales decline and a 6% drop in operating profit, but these still beat the company's projections. Based on this momentum, Novo revised its 2026 outlook, now forecasting adjusted sales and profit declines of 4% to 12%, an improvement from the previous 5% to 13% range. The market responded favorably, with shares climbing over 5% on the news.
The strong performance, particularly in the weight-loss pill segment, has been a catalyst for the raised guidance. Doustdar noted in the earnings report: "The strong Wegovy performance, combined with continued growth in international operations, has led us to raise our 2026 guidance for both adjusted sales and adjusted operating profit." This reflects confidence in the pill's ability to sustain growth amid evolving market dynamics.
Market Dynamics and Competitive Pressure
Novo Nordisk's stock had slumped over the past year, struggling to regain the heights reached in 2024 when GLP-1 medications first exploded in popularity. In contrast, American rival Eli Lilly has seen steady share gains, partly due to its own weight-loss drugs like Zepbound. In April, Lilly launched its own oral weight-loss medication, Foundayo, directly challenging Novo's pill strategy.
The competitive landscape shifted as Novo became a victim of its own success. Overwhelming demand for Wegovy and Ozempic led to production bottlenecks, fueling the rise of compounding pharmacies and allowing Eli Lilly to capture market share. To address this, Novo replaced longtime CEO Lars Fruergaard Jørgensen with Mike Doustdar last year, signaling a strategic pivot. Doustdar's focus has been on expanding manufacturing capacity and leveraging the pill to widen the patient base.
The Pill vs. Injection Debate
A key question is whether the pill will replace injections or expand the overall market. Novo claims that the pill is having a "synergistic effect" rather than cannibalization, as Doustdar told CNBC. Early data suggests that many new prescriptions come from patients who were previously not using GLP-1 therapies, potentially opening up a larger addressable market. However, analysts remain cautious, noting that Eli Lilly's entry with Foundayo could limit Novo's advantage.
Pill form offers convenience and reduces injection aversion, but efficacy differences may influence patient and physician choices. Novo's high-dose injectable Wegovy still offers potent results, while the pill targets a broader audience. The outcome of this competition will shape the next phase of the weight-loss drug boom.
Looking Ahead: The Post-Ozempic Era
The weight-loss drug market is entering a new phase beyond the Ozempic-driven frenzy. With multiple oral options now available, the landscape is becoming more diverse. Novo's pill strategy, combined with its manufacturing investments and leadership changes, aims to maintain its position. However, Eli Lilly's aggressive expansion and the potential for generic competition could reshape the market. For now, Novo's first-quarter results suggest that the pill boom is real, but sustaining momentum will require navigating supply chain challenges and competitive pricing.